Classic view of this page
Neurofibromatosis Type 2 (NF2) Next Genetration Sequencing and Deletion/Duplication Testing
Clinical Genetic Test
Help
offered by
Medical Genomics Laboratory
View lab's test page
LinkOut
GTR Test Accession: Help GTR000551653.6
INHERITED DISEASEINHERITED DISEASE SUSCEPTIBILITYCANCER ... View more
Last updated in GTR: 2023-06-07
View version history
Last annual review date for the lab: 2023-06-07 Past due LinkOut
At a Glance
Test purpose: Help
Diagnosis; Mutation Confirmation
Conditions (1): Help
Neurofibromatosis, type 2
Genes (1): Help
NF2 (22q12.2)
Methods (2): Help
Molecular Genetics - Linkage analysis: Multiplex Ligation-dependent Probe Amplification (MLPA); ...
Target population: Help
Patients with one or more features associated with NF2-related schwannomatosis …
Clinical validity: Help
Not provided
Clinical utility: Help
Establish or confirm diagnosis
Ordering Information
Offered by: Help
Medical Genomics Laboratory
View lab's website
View lab's test page
Test short name: Help
NF2-NG
Specimen Source: Help
Who can order: Help
  • Genetic Counselor
  • Health Care Provider
  • Licensed Physician
  • Nurse Practitioner
Test Order Code: Help
NF2-NG
View other test codes
CPT codes: Help
**AMA CPT codes notice

Copyright: 2023 American Medical Association. All rights reserved.

Lab contact: Help
Bryce Brown, MS, CGC, Certified Genetic counselor, CGC, Genetic Counselor
ebfincher@uabmc.edu
205-934-5525
Brandon Shaw, MS, CGC, Certified Genetic counselor, CGC, Genetic Counselor
brandonshaw@uabmc.edu
205-934-1520
Contact Policy: Help
Pre-test email/phone consultation regarding genetic test results and interpretation is provided to patients/families.
How to Order: Help
Additional information regarding the specific details needed for test submission can be found on our website
Order URL
Test development: Help
Test developed by laboratory (no manufacturer test name)
Informed consent required: Help
Based on applicable state law
Test strategy: Help
The NF2-only by NGS involves sequencing as well as deletion/duplication analysis of the entire coding NF2 region. The test uses an extensively customized and optimized set of Agilent HaloPlex capture probes, followed by sequencing of overlapping amplicons within the regions of interest using 300bp paired-end Illumina sequencing chemistry. Each coding … View more
View citations (1)
  • Should NF2 mutation screening be undertaken in patients with an apparently isolated vestibular schwannoma?. Evans DG, et al. Clin Genet. 2007;71(4):354-8. doi:10.1111/j.1399-0004.2007.00778.x. PMID: 17470137.
Pre-test genetic counseling required: Help
Decline to answer
Post-test genetic counseling required: Help
Decline to answer
Conditions Help
Total conditions: 1
Condition/Phenotype Identifier
Test Targets
Genes Help
Total genes: 1
Gene Associated Condition Germline or Somatic Allele (Lab-provided) Variant in NCBI
Methodology
Total methods: 2
Method Category Help
Test method Help
Instrument *
Linkage analysis
Multiplex Ligation-dependent Probe Amplification (MLPA)
Sequence analysis of the entire coding region
Next-Generation (NGS)/Massively parallel sequencing (MPS)
* Instrument: Not provided
Clinical Information
Test purpose: Help
Diagnosis; Mutation Confirmation
Clinical utility: Help
Establish or confirm diagnosis
View citations (1)

Target population: Help
Patients with one or more features associated with NF2-related schwannomatosis with or without a family history of NF2-related schwannomatosis.
Variant Interpretation:
What is the protocol for interpreting a variation as a VUS? Help
In order to further investigate a VUS, the laboratory will: 1. Review software predictions (SIFT, PolyPhen, etc) 2. Review internal database to compare against alterations seen in >10,000 alleles previously tested in laboratory 3. Offer free of charge family studies for any individuals that would provide useful information for interpretation

Are family members with defined clinical status recruited to assess significance of VUS without charge? Help
Yes.

Will the lab re-contact the ordering physician if variant interpretation changes? Help
Yes.
Recommended fields not provided:
Clinical validity, Is research allowed on the sample after clinical testing is complete?, Sample negative report, Sample positive report
Technical Information
Test Procedure: Help
The NF2-only by NGS involves sequencing as well as deletion/duplication analysis of the entire coding NF2 region. The test uses an extensively customized and optimized set of Agilent HaloPlex capture probes, followed by sequencing of overlapping amplicons within the regions of interest using 300bp paired-end Illumina sequencing chemistry. Each coding … View more
View citations (3)
  • Baser ME, Friedman JM, Aeschliman D, Joe H, Wallace AJ, Ramsden RT, Evans DG. Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet. 2002;71(4):715-23. doi:10.1086/342716. Epub 2002 Aug 22. PMID: 12235555.
  • Screening for large mutations of the NF2 gene. Kluwe L, et al. Genes Chromosomes Cancer. 2005;42(4):384-91. doi:10.1002/gcc.20138. PMID: 15645494.
  • Should NF2 mutation screening be undertaken in patients with an apparently isolated vestibular schwannoma?. Evans DG, et al. Clin Genet. 2007;71(4):354-8. doi:10.1111/j.1399-0004.2007.00778.x. PMID: 17470137.
Availability: Help
Tests performed
Entire test performed in-house
Analytical Validity: Help
Analytical sensitivity of next generation sequencing is typically validated using a minimum of 20 DNA samples. No false positives were detected during analysis. The average coverage is >2200x with 100% of the NF2 coding region ≥350x. The This allows for detection of very low-level mosaicism by sequencing (as low as … View more
View citations (1)
  • Should NF2 mutation screening be undertaken in patients with an apparently isolated vestibular schwannoma?. Evans DG, et al. Clin Genet. 2007;71(4):354-8. doi:10.1111/j.1399-0004.2007.00778.x. PMID: 17470137.
Proficiency testing (PT):
Is proficiency testing performed for this test? Help
Yes

Method used for proficiency testing: Help
Intra-Laboratory
VUS:
Software used to interpret novel variations Help
Alamut, Google search, PolyPhen, SIFT, evolutionary consevation, grantham score, splicing prediction software, disorder specific databases as necessary

Laboratory's policy on reporting novel variations Help
The laboratory will issue an interim report summarizing what is currently known about the variant and familial studies will be offered. Upon completion of the familial studies, a final report will be provided with a conclusion of what is suspected for the alteration.
Recommended fields not provided:
Test Confirmation, Assay limitations, Description of internal test validation method, PT Provider, Description of PT method, Major CAP category, CAP category, CAP test list
Regulatory Approval
FDA Review: Help
Category: FDA exercises enforcement discretion
Additional Information

IMPORTANT NOTE: NIH does not independently verify information submitted to GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.